BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management. Aliment Pharmacol Ther 2016;43:30-51. [PMID: 26515897 DOI: 10.1111/apt.13445] [Cited by in Crossref: 156] [Cited by in F6Publishing: 136] [Article Influence: 26.0] [Reference Citation Analysis]
Number Citing Articles
1 Dreesen E, Van Stappen T, Ballet V, Peeters M, Compernolle G, Tops S, Van Steen K, Van Assche G, Ferrante M, Vermeire S, Gils A. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response. Aliment Pharmacol Ther 2018;47:346-55. [DOI: 10.1111/apt.14452] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
2 Watanabe K, Matsumoto T, Hisamatsu T, Nakase H, Motoya S, Yoshimura N, Ishida T, Kato S, Nakagawa T, Esaki M, Nagahori M, Matsui T, Naito Y, Kanai T, Suzuki Y, Nojima M, Watanabe M, Hibi T; DIAMOND study group. Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2018;16:542-549.e1. [PMID: 29104132 DOI: 10.1016/j.cgh.2017.10.036] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
3 Retnakumar SV, Muller S. Pharmacological Autophagy Regulators as Therapeutic Agents for Inflammatory Bowel Diseases. Trends Mol Med 2019;25:516-37. [PMID: 30952481 DOI: 10.1016/j.molmed.2019.03.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
4 Marafini I, Monteleone G. Precision Medicine in Inflammatory Bowel Diseases. Front Pharmacol 2021;12:653924. [PMID: 33927628 DOI: 10.3389/fphar.2021.653924] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Thomas PWA, Chin PKL, Barclay ML. A nationwide survey on therapeutic drug monitoring of anti-tumour necrosis factor agents for inflammatory bowel disease. Intern Med J 2021;51:341-7. [PMID: 32043746 DOI: 10.1111/imj.14778] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Ishida N, Miyazu T, Sugiyama T, Tamura S, Kagami T, Tani S, Yamade M, Iwaizumi M, Hamaya Y, Osawa S, Furuta T, Sugimoto K. The effect of early trough level of infliximab on subsequent disease course in patients with Crohn disease: A prospective cohort study. Medicine (Baltimore) 2020;99:e21226. [PMID: 32702894 DOI: 10.1097/MD.0000000000021226] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Eberl A, Hallinen T, Af Björkesten CG, Heikkinen M, Hirsi E, Kellokumpu M, Koskinen I, Moilanen V, Nielsen C, Nuutinen H, Suhonen UM, Utriainen K, Vihriälä I, Soini E, Wennerström C, Nissinen R, Borsi A, Koivunen M, Tillonen J, Sipponen T. Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE). Scand J Gastroenterol 2019;54:718-25. [PMID: 31184512 DOI: 10.1080/00365521.2019.1624817] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
8 Ricciuto A, Dhaliwal J, Walters TD, Griffiths AM, Church PC. Clinical Outcomes With Therapeutic Drug Monitoring in Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis. J Crohns Colitis 2018;12:1302-15. [PMID: 30107416 DOI: 10.1093/ecco-jcc/jjy109] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 17.0] [Reference Citation Analysis]
9 Ding NS, Malietzis G, Lung PFC, Penez L, Yip WM, Gabe S, Jenkins JT, Hart A. The body composition profile is associated with response to anti-TNF therapy in Crohn's disease and may offer an alternative dosing paradigm. Aliment Pharmacol Ther 2017;46:883-91. [PMID: 28881017 DOI: 10.1111/apt.14293] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
10 Peyrin-biroulet L, Danese S, Argollo M, Pouillon L, Peppas S, Gonzalez-lorenzo M, Lytras T, Bonovas S. Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn’s Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2019;17:838-846.e2. [DOI: 10.1016/j.cgh.2018.06.026] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 27.0] [Reference Citation Analysis]
11 Danese S, Vermeire S, Hellstern P, Panaccione R, Rogler G, Fraser G, Kohn A, Desreumaux P, Leong RW, Comer GM, Cataldi F, Banerjee A, Maguire MK, Li C, Rath N, Beebe J, Schreiber S. Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn's disease (ANDANTE I and II). Gut. 2019;68:40-48. [PMID: 29247068 DOI: 10.1136/gutjnl-2017-314562] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 14.0] [Reference Citation Analysis]
12 Mazza S, Piazza O Sed N, Conforti FS, Fascì A, Rimondi A, Marinoni B, Casini V, Ricci C, Munari F, Pirola L, Invernizzi P, Girelli C, Lupinacci G, Pastorelli L, Cavallaro F, Ferraris L, Colucci A, Amato A, Eugenio Tontini G, Vecchi M, Fiorino G, Caprioli F. Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study. Clin Transl Sci 2021. [PMID: 34523800 DOI: 10.1111/cts.13131] [Reference Citation Analysis]
13 Richter F, Williams SK, John K, Huber C, Vaslin C, Zanker H, Fairless R, Pichi K, Marhenke S, Vogel A, Dhaen MA, Herrmann S, Herrmann A, Pfizenmaier K, Bantel H, Diem R, Kontermann RE, Fischer R. The TNFR1 Antagonist Atrosimab Is Therapeutic in Mouse Models of Acute and Chronic Inflammation. Front Immunol 2021;12:705485. [PMID: 34305946 DOI: 10.3389/fimmu.2021.705485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Fitzpatrick LR, Small J, O'Connell R, Talbott G, Alton G, Zapf J. VPR-254: an inhibitor of ROR-gamma T with potential utility for the treatment of inflammatory bowel disease. Inflammopharmacology 2020;28:499-511. [PMID: 31549280 DOI: 10.1007/s10787-019-00643-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Digby-Bell JL, Atreya R, Monteleone G, Powell N. Interrogating host immunity to predict treatment response in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2020;17:9-20. [PMID: 31767987 DOI: 10.1038/s41575-019-0228-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 14.0] [Reference Citation Analysis]
16 Hirai F, Ishida T, Takeshima F, Yamamoto S, Yoshikawa I, Ashizuka S, Inatsu H, Mitsuyama K, Sou S, Iwakiri R, Nozaki R, Ohi H, Esaki M, Iida M, Matsui T; Additional Power of Elemental Diet on Maintenance Biologics Therapy in Crohn's Disease (ADORE) Study Group. Effect of a concomitant elemental diet with maintenance anti-tumor necrosis factor-α antibody therapy in patients with Crohn's disease: A multicenter, prospective cohort study. J Gastroenterol Hepatol 2019;34:132-9. [PMID: 29935082 DOI: 10.1111/jgh.14361] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
17 Asadipour E, Kargar M. Drug survival of infliximab and adalimumab in inflammatory bowel disease. Int J Clin Pharm 2020;42:1521-3. [PMID: 33085041 DOI: 10.1007/s11096-020-01151-9] [Reference Citation Analysis]
18 Kopylov U, Seidman E. Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. Therap Adv Gastroenterol 2016;9:513-26. [PMID: 27366220 DOI: 10.1177/1756283X16638833] [Cited by in Crossref: 33] [Cited by in F6Publishing: 14] [Article Influence: 6.6] [Reference Citation Analysis]
19 Papamichael K, Cheifetz AS. Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?Curr Opin Gastroenterol. 2019;35:302-310. [PMID: 30973355 DOI: 10.1097/MOG.0000000000000536] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
20 Pavlidis P, Gulati S, Dubois P, Chung-faye G, Sherwood R, Bjarnason I, Hayee B. Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn’s disease. Scandinavian Journal of Gastroenterology 2016;51:1447-52. [DOI: 10.1080/00365521.2016.1205128] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
21 Alsoud D, Vermeire S, Verstockt B. Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope?Curr Opin Pharmacol. 2020;55:17-30. [PMID: 33039940 DOI: 10.1016/j.coph.2020.09.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
22 Kothari MM, Nguyen DL, Parekh NK. Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature. World J Gastrointest Pharmacol Ther 2017; 8(3): 155-161 [PMID: 28828193 DOI: 10.4292/wjgpt.v8.i3.155] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
23 Frymoyer A, Hoekman DR, Piester TL, de Meij TG, Hummel TZ, Benninga MA, Kindermann A, Park KT. Application of Population Pharmacokinetic Modeling for Individualized Infliximab Dosing Strategies in Crohn Disease. J Pediatr Gastroenterol Nutr 2017;65:639-45. [PMID: 28471911 DOI: 10.1097/MPG.0000000000001620] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
24 Ponsioen CY, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Bossuyt PMM, Hart A, Warusavitarne J, Buskens CJ, van Bodegraven AA, Brink MA, Consten ECJ, van Wagensveld BA, Rijk MCM, Crolla RMPH, Noomen CG, Houdijk APJ, Mallant RC, Boom M, Marsman WA, Stockmann HB, Mol B, de Groof AJ, Stokkers PC, D'Haens GR, Bemelman WA; LIR!C study group. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol Hepatol 2017;2:785-92. [PMID: 28838644 DOI: 10.1016/S2468-1253(17)30248-0] [Cited by in Crossref: 90] [Cited by in F6Publishing: 32] [Article Influence: 22.5] [Reference Citation Analysis]
25 Alfaro I, Masamunt MC, Planell N, López-García A, Castro J, Gallego M, Barastegui R, Giner A, Vara A, Salas A, Ricart E, Panés J, Ordás I. Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn’s disease. World J Gastroenterol 2019; 25(14): 1764-1774 [PMID: 31011260 DOI: 10.3748/wjg.v25.i14.1764] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Segal AW. Studies on patients establish Crohn's disease as a manifestation of impaired innate immunity. J Intern Med 2019;286:373-88. [DOI: 10.1111/joim.12945] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
27 Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, Whitehead D, Hudesman D, Lukin D, Swaminath A, Shmidt E, Wang S, Boland BS, Chang JT, Kane S, Siegel CA, Loftus EV, Sandborn WJ, Sands BE, Colombel JF. The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium. Am J Gastroenterol. 2016;111:1147-1155. [PMID: 27296941 DOI: 10.1038/ajg.2016.236] [Cited by in Crossref: 184] [Cited by in F6Publishing: 162] [Article Influence: 36.8] [Reference Citation Analysis]
28 Tarnok A, Kiss Z, Kadenczki O, Veres G. Characteristics of biological therapy in pediatric patients with Crohn's disease. Expert Opin Biol Ther 2019;19:181-96. [PMID: 30601083 DOI: 10.1080/14712598.2019.1564034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
29 Pouillon L, Ferrante M, Van Assche G, Rutgeerts P, Noman M, Sabino J, Vande Casteele N, Gils A, Vermeire S. Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab. Clin Gastroenterol Hepatol 2018;16:1276-1283.e1. [PMID: 29203225 DOI: 10.1016/j.cgh.2017.11.046] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
30 Hedin CRH, Sonkoly E, Eberhardson M, Ståhle M. Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approach. J Intern Med 2021;290:257-78. [PMID: 33942408 DOI: 10.1111/joim.13282] [Reference Citation Analysis]
31 Kang B, Choi SY, Choi YO, Lee SY, Baek SY, Sohn I, Choe BH, Lee HJ, Choe YH. Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn's Disease. J Crohns Colitis. 2019;13:189-197. [PMID: 30452616 DOI: 10.1093/ecco-jcc/jjy155] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
32 Cha M, Kwon M, Park M, Oh JH, Sung KK, Lee BH. Combined treatment of Taraxaci Herba and R7050 alleviates the symptoms of herpes simplex virus-induced Behçet's disease in rats. Integr Med Res 2021;10:100720. [PMID: 33898245 DOI: 10.1016/j.imr.2021.100720] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Aardoom MA, Veereman G, de Ridder L. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease. Int J Mol Sci 2019;20:E2529. [PMID: 31126015 DOI: 10.3390/ijms20102529] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
34 Franca R, Curci D, Lucafò M, Decorti G, Stocco G. Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric inflammatory bowel disease. Expert Opin Drug Metab Toxicol 2019;15:527-39. [PMID: 31177858 DOI: 10.1080/17425255.2019.1630378] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
35 Af Björkesten CG, Ilus T, Hallinen T, Soini E, Eberl A, Hakala K, Heikura M, Jussila A, Koskela R, Koskinen I, Moilanen V, Nielsen C, Nieminen U, Nuutinen H, Heikkinen M, Suhonen UM, Tillonen J, Utriainen K, Vihriälä I, Wennerström C, Borsi A, Nissinen R, Koivunen MR, Sipponen T. Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohort. Eur J Gastroenterol Hepatol 2020;32:1507-13. [PMID: 32868649 DOI: 10.1097/MEG.0000000000001831] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
36 Iborra M, Beltrán B, Fernández-Clotet A, Gutiérrez A, Antolín B, Huguet JM, De Francisco R, Merino O, Carpio D, García-López S, Mesonero F, Navarro P, Ferreiro-Iglesias R, Carbajo AY, Rivero M, Gisbert JP, Piñero-Pérez MC, Monfort D, Bujanda L, García-Sepulcre MF, Martín-Cardona A, Cañete F, Taxonera C, Domènech E, Nos P; GETECCU Group (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa). Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry. Aliment Pharmacol Ther 2019;50:278-88. [PMID: 31222872 DOI: 10.1111/apt.15371] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 14.5] [Reference Citation Analysis]
37 Steeland S, Libert C, Vandenbroucke RE. A New Venue of TNF Targeting. Int J Mol Sci 2018;19:E1442. [PMID: 29751683 DOI: 10.3390/ijms19051442] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 17.3] [Reference Citation Analysis]
38 Kim KU, Kim J, Kim WH, Min H, Choi CH. Treatments of inflammatory bowel disease toward personalized medicine. Arch Pharm Res 2021;44:293-309. [PMID: 33763844 DOI: 10.1007/s12272-021-01318-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Mohammad Jafari R, Shayesteh S, Ala M, Yousefi-Manesh H, Rashidian A, Hashemian SM, Sorouri M, Dehpour AR. Dapsone Ameliorates Colitis through TLR4/NF-kB Pathway in TNBS Induced Colitis Model in Rat. Arch Med Res 2021;52:595-602. [PMID: 33814208 DOI: 10.1016/j.arcmed.2021.03.005] [Reference Citation Analysis]
40 Razvi M, Lazarev M. Optimization of biologic therapy in Crohn’s disease. Expert Opinion on Biological Therapy 2017;18:263-72. [DOI: 10.1080/14712598.2018.1410131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
41 Pinto Pais I, Espinheira MC, Trindade E, Amil Dias J. Optimizing Antitumor Necrosis Factor Treatment in Pediatric Inflammatory Bowel Disease With Therapeutic Drug Monitoring. J Pediatr Gastroenterol Nutr 2020;71:12-8. [PMID: 32142005 DOI: 10.1097/MPG.0000000000002704] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Gisbert JP, Chaparro M. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 2020;14:694-709. [DOI: 10.1093/ecco-jcc/jjz195] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 19.0] [Reference Citation Analysis]
43 Fobelo Lozano MJ, Serrano Giménez R, Sánchez Fidalgo S. Therapeutic drug monitoring of infliximab in spondyloarthritis. A review of the literature. Br J Clin Pharmacol 2019;85:2264-79. [PMID: 31315147 DOI: 10.1111/bcp.14062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
44 Holt DQ, Varma P, Strauss BJG, Rajadurai AS, Moore GT. Low muscle mass at initiation of anti-TNF therapy for inflammatory bowel disease is associated with early treatment failure: a retrospective analysis. Eur J Clin Nutr 2017;71:773-7. [PMID: 28225051 DOI: 10.1038/ejcn.2017.10] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
45 van der Gugten JG, Bressler B, Demarco ML. An automated mass spectrometric blood test for therapeutic drug monitoring of infliximab. Clinical Mass Spectrometry 2019;12:16-22. [DOI: 10.1016/j.clinms.2019.01.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
46 Faelens R, Wang Z, Bouillon T, Declerck P, Ferrante M, Vermeire S, Dreesen E. Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis. Pharmaceutics 2021;13:1623. [PMID: 34683916 DOI: 10.3390/pharmaceutics13101623] [Reference Citation Analysis]
47 Marquez-Megias S, Ramon-Lopez A, Más-Serrano P, Diaz-Gonzalez M, Candela-Boix MR, Nalda-Molina R. Evaluation of the Predictive Performance of Population Pharmacokinetic Models of Adalimumab in Patients with Inflammatory Bowel Disease. Pharmaceutics 2021;13:1244. [PMID: 34452204 DOI: 10.3390/pharmaceutics13081244] [Reference Citation Analysis]
48 Rimola J, Fernàndez-Clotet A, Capozzi N, Rojas-Farreras S, Alfaro I, Rodríguez S, Masamunt MC, Ricart E, Ordás I, Panés J. Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease. Aliment Pharmacol Ther 2020;52:1563-73. [PMID: 32886809 DOI: 10.1111/apt.16069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Curci D, Lucafò M, Cifù A, Bramuzzo M, Martelossi S, Favretto D, De Pellegrin F, Fabris M, Vascotto F, Naviglio S, Ventura A, Stocco G, Decorti G. Determination of Serum Infliximab Concentration by Point-of-care Devices in Children With Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology & Nutrition 2019;69:474-9. [DOI: 10.1097/mpg.0000000000002410] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
50 Kamperidis N, Middleton P, Tyrrell T, Stasinos I, Arebi N. Impact of therapeutic drug level monitoring on outcomes of patients with Crohn's disease treated with Infliximab: real world data from a retrospective single centre cohort study. Frontline Gastroenterol 2019;10:330-6. [PMID: 31682652 DOI: 10.1136/flgastro-2018-101024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
51 Iijima H, Kobayashi T, Nagasaka M, Shinzaki S, Kitamura K, Suzuki Y, Watanabe M, Hibi T. Management of Primary Nonresponders and Partial Responders to Tumor Necrosis Factor-α Inhibitor Induction Therapy among Patients with Crohn's Disease. Inflamm Intest Dis 2020;5:78-83. [PMID: 32596258 DOI: 10.1159/000506337] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Armuzzi A, Fiorino G, Variola A, Manetti N, Fries W, Orlando A, Maconi G, Bossa F, Cappello M, Biancone L, Cantoro L, Costa F, D’incà R, Lionetti P, Principi M, Castiglione F, Annunziata ML, Di Sabatino A, Di Girolamo M, Terpin MM, Cortelezzi CC, Saibeni S, Amato A, Ardizzone S, Guidi L, Danese S, Massella A, Ventra A, Rizzuto G, Massari A, Perri F, Annese V, Saettone S, Tari R, Petruzzellis C, Meucci G, Imperiali G, Guglielmi FW, Mazzuoli S, Caserta L, Caterina Parodi M, Colli A, Ronchetti A, Pugliese D, Geccherle A, Rogai F, Milani S, Renna S, Cassinotti A, Andriulli A, Martino G, Scrivo B, Troncone E, Kohn A, Bertani L, Lorenzon G, Ghione S, Nardone O, Vecchi M, Bertani A, Bosani MA, Bezzio C, Salerno R; PROSIT Investigators. The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. Inflammatory Bowel Diseases 2019;25:568-79. [DOI: 10.1093/ibd/izy264] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
53 Naviglio S, Lacorte D, Lucafò M, Cifù A, Favretto D, Cuzzoni E, Silvestri T, Pozzi Mucelli M, Radillo O, Decorti G, Fabris M, Bramuzzo M, Taddio A, Stocco G, Alvisi P, Ventura A, Martelossi S. Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab: A Pharmacokinetic Study. Journal of Pediatric Gastroenterology & Nutrition 2019;68:37-44. [DOI: 10.1097/mpg.0000000000002112] [Cited by in Crossref: 26] [Cited by in F6Publishing: 8] [Article Influence: 13.0] [Reference Citation Analysis]
54 Ding NS, McDonald JAK, Perdones-Montero A, Rees DN, Adegbola SO, Misra R, Hendy P, Penez L, Marchesi JR, Holmes E, Sarafian MH, Hart AL. Metabonomics and the Gut Microbiome Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease. J Crohns Colitis 2020;14:1090-102. [PMID: 32119090 DOI: 10.1093/ecco-jcc/jjaa039] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
55 Assa A, Bronsky J, Kolho KL, Zarubova K, de Meij T, Ledder O, Sladek M, van Biervliet S, Strisciuglio C, Shamir R. Anti-TNFα Treatment After Surgical Resection for Crohn's Disease Is Effective Despite Previous Pharmacodynamic Failure. Inflamm Bowel Dis 2017;23:791-7. [PMID: 28426458 DOI: 10.1097/MIB.0000000000001050] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Liu Y, Duan Y, Li Y. Integrated Gene Expression Profiling Analysis Reveals Probable Molecular Mechanism and Candidate Biomarker in Anti-TNFα Non-Response IBD Patients. J Inflamm Res 2020;13:81-95. [PMID: 32104045 DOI: 10.2147/JIR.S236262] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
57 Soendergaard C, Bergenheim FH, Bjerrum JT, Nielsen OH. Targeting JAK-STAT signal transduction in IBD. Pharmacol Ther. 2018;192:100-111. [PMID: 30048708 DOI: 10.1016/j.pharmthera.2018.07.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 12.3] [Reference Citation Analysis]
58 Jung ES, Choi KW, Kim SW, Hübenthal M, Mucha S, Park J, Park Z, Ellinghaus D, Schreiber S, Franke A, Oh WY, Cheon JH. ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases. J Gastroenterol Hepatol 2019;34:1727-35. [PMID: 30851117 DOI: 10.1111/jgh.14652] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
59 Hamminger P, Rica R, Ellmeier W. Histone deacetylases as targets in autoimmune and autoinflammatory diseases. Adv Immunol 2020;147:1-59. [PMID: 32981634 DOI: 10.1016/bs.ai.2020.06.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
60 Hirai F, Takeda T, Takada Y, Kishi M, Beppu T, Takatsu N, Miyaoka M, Hisabe T, Yao K, Ueki T. Efficacy of enteral nutrition in patients with Crohn's disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysis. J Gastroenterol 2020;55:133-41. [PMID: 31641874 DOI: 10.1007/s00535-019-01634-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
61 Segal AW. Making sense of the cause of Crohn's - a new look at an old disease. F1000Res 2016;5:2510. [PMID: 28105308 DOI: 10.12688/f1000research.9699.2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
62 Shim HH, Chan PW, Chuah SW, Schwender BJ, Kong SC, Ling KL. A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases. JGH Open 2018;2:223-34. [PMID: 30483594 DOI: 10.1002/jgh3.12065] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
63 Khoury O, Atala A, Murphy SV. Stromal cells from perinatal and adult sources modulate the inflammatory immune response in vitro by decreasing Th1 cell proliferation and cytokine secretion. Stem Cells Transl Med 2020;9:61-73. [PMID: 31638323 DOI: 10.1002/sctm.19-0123] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
64 Taylor H, Serrano-Contreras JI, McDonald JAK, Epstein J, Fell JM, Seoane RC, Li JV, Marchesi JR, Hart AL. Multiomic features associated with mucosal healing and inflammation in paediatric Crohn's disease. Aliment Pharmacol Ther 2020;52:1491-502. [PMID: 32929796 DOI: 10.1111/apt.16086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Bek S, Nielsen JV, Bojesen AB, Franke A, Bank S, Vogel U, Andersen V. Systematic review: Genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;44:554-567. [PMID: 27417569 DOI: 10.1111/apt.13736] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 11.6] [Reference Citation Analysis]
66 Kang B, Choi SY, Choi YO, Kim M, Kim K, Lee J, Choe YH. Subtherapeutic Infliximab Trough Levels and Complete Mucosal Healing Are Associated With Sustained Clinical Remission After Infliximab Cessation in Paediatric-onset Crohn’s Disease Patients Treated With Combined Immunosuppressive Therapy. Journal of Crohn's and Colitis 2018;12:644-52. [DOI: 10.1093/ecco-jcc/jjy021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
67 Aggeletopoulou I, Assimakopoulos SF, Konstantakis C, Triantos C. Interleukin 12/interleukin 23 pathway: Biological basis and therapeutic effect in patients with Crohn's disease. World J Gastroenterol 2018; 24(36): 4093-4103 [PMID: 30271076 DOI: 10.3748/wjg.v24.i36.4093] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
68 Abraham C, Dulai PS, Vermeire S, Sandborn WJ. Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases. Gastroenterology 2017;152:374-388.e4. [PMID: 27780712 DOI: 10.1053/j.gastro.2016.10.018] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 14.4] [Reference Citation Analysis]
69 Jarosz-Griffiths HH, Holbrook J, Lara-Reyna S, McDermott MF. TNF receptor signalling in autoinflammatory diseases. Int Immunol 2019;31:639-48. [PMID: 30838383 DOI: 10.1093/intimm/dxz024] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 22.0] [Reference Citation Analysis]
70 Madsen KG, Pottegård A, Hallas J, Kjeldsen J. Treatment Failure of TNF-α Inhibitors in Obese Patients With Inflammatory Bowel Disease—A Cohort Study. Inflammatory Bowel Diseases 2018;24:2628-33. [DOI: 10.1093/ibd/izy178] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
71 Guerrero Puente L, Iglesias Flores E, Benítez JM, Medina Medina R, Salgueiro Rodríguez I, Aguilar Melero P, Cárdenas Aranzana MJ, González Fernández R, Manzanares Martin B, García-Sánchez V. Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission. Gastroenterol Hepatol 2017;40:595-604. [PMID: 28865888 DOI: 10.1016/j.gastrohep.2017.07.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
72 Patel H, Lissoos T, Rubin DT. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States. PLoS One 2017;12:e0175099. [PMID: 28426675 DOI: 10.1371/journal.pone.0175099] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
73 Papaconstantinou I, Kapizioni C, Legaki E, Xourgia E, Karamanolis G, Gklavas A, Gazouli M. Association of miR-146 rs2910164, miR-196a rs11614913, miR-221 rs113054794 and miR-224 rs188519172 polymorphisms with anti-TNF treatment response in a Greek population with Crohn’s disease. World J Gastrointest Pharmacol Ther 2017; 8(4): 193-200 [PMID: 29152405 DOI: 10.4292/wjgpt.v8.i4.193] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
74 Guberna L, Nyssen OP, Chaparro M, Gisbert JP. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. J Clin Med 2021;10:2132. [PMID: 34069295 DOI: 10.3390/jcm10102132] [Reference Citation Analysis]
75 Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, Barclay M, Begun J, Bryant R, Chan W, Corte C, Ghaly S, Lemberg DA, Kariyawasam V, Lewindon P, Martin J, Mountifield R, Radford-Smith G, Slobodian P, Sparrow M, Toong C, van Langenberg D, Ward MG, Leong RW; IBD Sydney Organisation and the Australian Inflammatory Bowel Diseases Consensus Working Group. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther 2017;46:1037-53. [PMID: 29027257 DOI: 10.1111/apt.14368] [Cited by in Crossref: 144] [Cited by in F6Publishing: 120] [Article Influence: 36.0] [Reference Citation Analysis]
76 Naviglio S, Giuffrida P, Stocco G, Lenti MV, Ventura A, Corazza GR, Di Sabatino A. How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 2018;12:797-810. [DOI: 10.1080/17474124.2018.1494573] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
77 Papamichael K, Cheifetz AS. Use of anti-TNF drug levels to optimise patient management. Frontline Gastroenterol. 2016;7:289-300. [PMID: 28839870 DOI: 10.1136/flgastro-2016-100685] [Cited by in Crossref: 60] [Cited by in F6Publishing: 47] [Article Influence: 12.0] [Reference Citation Analysis]
78 Sigall Boneh R, Sarbagili Shabat C, Yanai H, Chermesh I, Ben Avraham S, Boaz M, Levine A. Dietary Therapy With the Crohn's Disease Exclusion Diet is a Successful Strategy for Induction of Remission in Children and Adults Failing Biological Therapy. J Crohns Colitis. 2017;11:1205-1212. [PMID: 28525622 DOI: 10.1093/ecco-jcc/jjx071] [Cited by in Crossref: 63] [Cited by in F6Publishing: 41] [Article Influence: 21.0] [Reference Citation Analysis]
79 Reinisch W, Gecse K, Halfvarson J, Irving PM, Jahnsen J, Peyrin-Biroulet L, Rogler G, Schreiber S, Danese S. Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. Inflamm Bowel Dis 2021;27:106-22. [PMID: 32634212 DOI: 10.1093/ibd/izaa078] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
80 Shi HY, Ng SC. The state of the art on treatment of Crohn's disease. J Gastroenterol. 2018;53:989-998. [PMID: 29980848 DOI: 10.1007/s00535-018-1479-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
81 Varma P, Rajadurai AS, Holt DQ, Devonshire DA, Desmond CP, Swan MP, Nathan D, Shelton ET, Prideaux L, Sorrell C, Rusli F, Crantock LRF, Dev A, Ratnam DT, Pianko S, Moore GT. Immunomodulator use does not prevent first loss of response to anti-tumour necrosis factor alpha therapy in inflammatory bowel disease: long-term outcomes in a real-world cohort. Intern Med J 2019;49:753-60. [PMID: 30381884 DOI: 10.1111/imj.14150] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
82 Khoury T, Ilan Y. Introducing Patterns of Variability for Overcoming Compensatory Adaptation of the Immune System to Immunomodulatory Agents: A Novel Method for Improving Clinical Response to Anti-TNF Therapies. Front Immunol 2019;10:2726. [PMID: 31824506 DOI: 10.3389/fimmu.2019.02726] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
83 Gofin Y, Matar M, Shamir R, Assa A. Therapeutic Drug Monitoring Increases Drug Retention of Anti–Tumor Necrosis Factor Alpha Agents in Pediatric Patients With Crohn’s Disease. Inflammatory Bowel Diseases 2019. [DOI: 10.1093/ibd/izz257] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
84 Mattoo VY, Basnayake C, Connell WR, Ding N, Kamm MA, Lust M, Niewiadomski O, Thompson A, Wright EK. Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn's disease. Aliment Pharmacol Ther 2021;54:249-66. [PMID: 34153124 DOI: 10.1111/apt.16479] [Reference Citation Analysis]
85 Lim Z, Welman CJ, Raymond W, Thin L. The Effect of Adiposity on Anti-Tumor Necrosis Factor-Alpha Levels and Loss of Response in Crohn's Disease Patients. Clin Transl Gastroenterol 2020;11:e00233. [PMID: 33094963 DOI: 10.14309/ctg.0000000000000233] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
86 Alric H, Amiot A, Kirchgesner J, Tréton X, Allez M, Bouhnik Y, Beaugerie L, Carbonnel F, Meyer A. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor.Aliment Pharmacol Ther. 2020;51:948-957. [PMID: 32249966 DOI: 10.1111/apt.15706] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 22.0] [Reference Citation Analysis]
87 Wang Y, Gao X, Zhang X, Xiao F, Hu H, Li X, Dong F, Sun M, Xiao Y, Ge T, Li D, Yu G, Liu Z, Zhang T. Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn's disease. Gut Microbes 2021;13:1-18. [PMID: 33430702 DOI: 10.1080/19490976.2020.1865708] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
88 Forss A, Clements M, Myrelid P, Strid H, Söderman C, Wagner A, Andersson D, Hjelm F, Olén O, Ludvigsson JF, Halfvarson J; PROSE SWIBREG study group. Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn's disease (PROSE): a 16-week follow-up. Scand J Gastroenterol 2021;56:680-6. [PMID: 33794731 DOI: 10.1080/00365521.2021.1906946] [Reference Citation Analysis]
89 Billiet T, Cleynen I, Ballet V, Ferrante M, Van Assche G, Gils A, Vermeire S. Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience. Aliment Pharmacol Ther 2016;44:673-83. [DOI: 10.1111/apt.13754] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
90 Segal AW. Making sense of the cause of Crohn's - a new look at an old disease. F1000Res. 2016;5:2510. [PMID: 28105308 DOI: 10.12688/f1000research.9699.2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
91 Argollo M, Kotze PG, Kakkadasam P, D'Haens G. Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? Nat Rev Gastroenterol Hepatol 2020;17:702-10. [PMID: 32879465 DOI: 10.1038/s41575-020-0352-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
92 Li L, Chen R, Zhang Y, Zhou G, Chen B, Zeng Z, Chen M, Zhang S. A Novel Model Based on Serum Biomarkers to Predict Primary Non-Response to Infliximab in Crohn's Disease. Front Immunol 2021;12:646673. [PMID: 34367126 DOI: 10.3389/fimmu.2021.646673] [Reference Citation Analysis]
93 Holleran G, Lopetuso L, Petito V, Graziani C, Ianiro G, McNamara D, Gasbarrini A, Scaldaferri F. The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease. Int J Mol Sci. 2017;18. [PMID: 28934123 DOI: 10.3390/ijms18102020] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
94 Clarkston K, Tsai YT, Jackson K, Rosen MJ, Denson LA, Minar P. Development of Infliximab Target Concentrations During Induction in Pediatric Crohn Disease Patients. J Pediatr Gastroenterol Nutr 2019;69:68-74. [PMID: 31232885 DOI: 10.1097/MPG.0000000000002304] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 19.0] [Reference Citation Analysis]
95 van Haaften WT, Mortensen JH, Dige AK, Grønbæk H, Hvas CL, Bay-Jensen AC, Karsdal MA, Olinga P, Manon-Jensen T, Dijkstra G. Serological Biomarkers of Tissue Turnover Identify Responders to Anti-TNF Therapy in Crohn's Disease: A Pilot Study. Clin Transl Gastroenterol 2020;11:e00217. [PMID: 33094957 DOI: 10.14309/ctg.0000000000000217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Lopetuso LR, Gerardi V, Papa V, Scaldaferri F, Rapaccini GL, Gasbarrini A, Papa A. Can We Predict the Efficacy of Anti-TNF-α Agents? Int J Mol Sci 2017;18:E1973. [PMID: 28906475 DOI: 10.3390/ijms18091973] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 10.8] [Reference Citation Analysis]
97 Dulai PS, Sandborn WJ. Next-Generation Therapeutics for Inflammatory Bowel Disease. Curr Gastroenterol Rep 2016;18:51. [PMID: 27461274 DOI: 10.1007/s11894-016-0522-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
98 Mitrev N, Leong RW. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease. Expert Opin Drug Saf 2017;16:303-17. [PMID: 27922765 DOI: 10.1080/14740338.2017.1269169] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
99 de Jong MJ, Pierik MJ, Peters A, Roemers M, Hilhorst V, van Tubergen A. Exploring conditions for redistribution of anti-tumor necrosis factors to reduce spillage: A study on the quality of anti-tumor necrosis factor home storage. J Gastroenterol Hepatol 2018;33:426-30. [PMID: 28800384 DOI: 10.1111/jgh.13920] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
100 Levy RA, Guzman R, Castañeda-Hernández G, Martinez-Vazquez M, Damian G, Cara C. Biology of anti-TNF agents in immune-mediated inflammatory diseases: therapeutic implications. Immunotherapy 2016;8:1427-36. [PMID: 27737604 DOI: 10.2217/imt-2016-0067] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
101 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H;  IBD guidelines eDelphi consensus group; Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 361] [Cited by in F6Publishing: 302] [Article Influence: 180.5] [Reference Citation Analysis]
102 Pan S, Tsakok T, Dand N, Lonsdale DO, Loeff FC, Bloem K, de Vries A, Baudry D, Duckworth M, Mahil S, Pushpa-Rajah A, Russell A, Alsharqi A, Becher G, Murphy R, Wahie S, Wright A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, David Burden A, Rispens T, Standing JF, Smith CH; BADBIR Study Group, the BSTOP Study Group, the PSORT Consortium. Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study. Clin Transl Sci 2020;13:400-9. [PMID: 31995663 DOI: 10.1111/cts.12725] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
103 Giuffrida P, Corazza GR, Di Sabatino A. Old and New Lymphocyte Players in Inflammatory Bowel Disease. Dig Dis Sci 2018;63:277-88. [DOI: 10.1007/s10620-017-4892-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 9.5] [Reference Citation Analysis]
104 Gisbert JP, Chaparro M. Clinical Usefulness of Proteomics in Inflammatory Bowel Disease: A Comprehensive Review.J Crohns Colitis. 2019;13:374-384. [PMID: 30307487 DOI: 10.1093/ecco-jcc/jjy158] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
105 Ward MG, Thwaites PA, Beswick L, Hogg J, Rosella G, Van Langenberg D, Reynolds J, Gibson PR, Sparrow MP. Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease. Aliment Pharmacol Ther 2017;45:1135-45. [PMID: 28239869 DOI: 10.1111/apt.13992] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
106 Kang B, Choi SY, Kim HS, Kim K, Lee YM, Choe YH. Mucosal Healing in Paediatric Patients with Moderate-to-Severe Luminal Crohn’s Disease Under Combined Immunosuppression: Escalation versus Early Treatment. ECCOJC 2016;10:1279-86. [DOI: 10.1093/ecco-jcc/jjw086] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 7.6] [Reference Citation Analysis]
107 Penagini F, Cococcioni L, Pozzi E, Dilillo D, Rendo G, Mantegazza C, Zuccotti GV. Biological therapy in pediatric age. Pharmacol Res 2020;161:105120. [PMID: 32783974 DOI: 10.1016/j.phrs.2020.105120] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
108 Deepak P, Sandborn WJ. Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease. Gastroenterol Clin North Am 2017;46:603-26. [PMID: 28838418 DOI: 10.1016/j.gtc.2017.05.013] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
109 Shen W, Cao L, Li Y, Cai X, Ge Y, Zhu W. Visceral Fat Is Associated With Mucosal Healing of Infliximab Treatment in Crohn’s Disease. Diseases of the Colon & Rectum 2018;61:706-12. [DOI: 10.1097/dcr.0000000000001074] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
110 Chen Y, Li H, Feng Q, Shen J. Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn's Disease Patients. Front Pharmacol 2021;12:654985. [PMID: 33986682 DOI: 10.3389/fphar.2021.654985] [Reference Citation Analysis]
111 Doecke JD, Hartnell F, Bampton P, Bell S, Mahy G, Grover Z, Lewindon P, Jones LV, Sewell K, Krishnaprasad K, Prosser R, Marr D, Fischer J, R Thomas G, Tehan JV, Ding NS, Cooke SE, Moss K, Sechi A, De Cruz P, Grafton R, Connor SJ, Lawrance IC, Gearry RB, Andrews JM, Radford-smith GL; the Australian and New Zealand Inflammatory Bowel Disease Consortium. Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study. Aliment Pharmacol Ther 2017;45:542-52. [DOI: 10.1111/apt.13880] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
112 Schulberg JD, Wright EK, Holt BA, Wilding HE, Hamilton AL, Ross AL, Kamm MA. Efficacy of drug and endoscopic treatment of Crohn's disease strictures: A systematic review. J Gastroenterol Hepatol 2021;36:344-61. [PMID: 33150989 DOI: 10.1111/jgh.15330] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
113 Ripollés T, Paredes JM, Martínez-Pérez MJ, Rimola J, Jauregui-Amezaga A, Bouzas R, Martin G, Moreno-Osset E. Ultrasonographic Changes at 12 Weeks of Anti-TNF Drugs Predict 1-year Sonographic Response and Clinical Outcome in Crohn's Disease: A Multicenter Study. Inflamm Bowel Dis 2016;22:2465-73. [PMID: 27580385 DOI: 10.1097/MIB.0000000000000882] [Cited by in Crossref: 38] [Cited by in F6Publishing: 9] [Article Influence: 12.7] [Reference Citation Analysis]
114 Rundquist S, Eriksson C, Nilsson L, Angelison L, Jäghult S, Björk J, Grip O, Hjortswang H, Strid H, Karlén P, Montgomery S, Halfvarson J. Clinical effectiveness of golimumab in Crohn’s disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG). Scandinavian Journal of Gastroenterology 2018;53:1257-63. [DOI: 10.1080/00365521.2018.1519597] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
115 Allard-Chamard H. Laboratory Testing in the Context of Biologics and Cellular Therapies. Clin Lab Med 2019;39:657-68. [PMID: 31668276 DOI: 10.1016/j.cll.2019.07.011] [Reference Citation Analysis]
116 Catalan-Serra I, Brenna Ø. Immunotherapy in inflammatory bowel disease: Novel and emerging treatments. Hum Vaccin Immunother 2018;14:2597-611. [PMID: 29624476 DOI: 10.1080/21645515.2018.1461297] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
117 Angus HCK, Butt AG, Schultz M, Kemp RA. Intestinal Organoids as a Tool for Inflammatory Bowel Disease Research. Front Med (Lausanne) 2019;6:334. [PMID: 32010704 DOI: 10.3389/fmed.2019.00334] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 16.0] [Reference Citation Analysis]
118 Dobranowski PA, Tang C, Sauvé JP, Menzies SC, Sly LM. Compositional changes to the ileal microbiome precede the onset of spontaneous ileitis in SHIP deficient mice. Gut Microbes 2019;10:578-98. [PMID: 30760087 DOI: 10.1080/19490976.2018.1560767] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
119 Törüner M, Akpınar H, Akyüz F, Dağlı Ü, Över Hamzaoğlu H, Tezel A, Ünsal B, Yıldırım S, Çelik AF. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turk J Gastroenterol 2019;30:S913-46. [PMID: 32207688 DOI: 10.5152/tjg.2019.061119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Jessen B, Rodriguez-Sillke Y, Sonnenberg E, Schumann M, Kruglov A, Freise I, Schmidt F, Maul J, Kühl AA, Glauben R, Lissner D, Siegmund B. Level of Tumor Necrosis Factor Production by Stimulated Blood Mononuclear Cells Can Be Used to Predict Response of Patients With Inflammatory Bowel Diseases to Infliximab. Clin Gastroenterol Hepatol 2021;19:721-731.e1. [PMID: 32272247 DOI: 10.1016/j.cgh.2020.03.066] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
121 Zapater P, Almenara S, Gutiérrez A, Sempere L, García M, Laveda R, Martínez A, Scharl M, Cameo JI, Linares R, González-Navajas JM, Wiest R, Rogler G, Francés R. Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease. Inflamm Bowel Dis 2019;25:1357-66. [PMID: 30776076 DOI: 10.1093/ibd/izz012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
122 Lv F, Yang L, Wang J, Chen Z, Sun Q, Zhang P, Guan C, Liu Y. Inhibition of TNFR1 Attenuates LPS Induced Apoptosis and Inflammation in Human Nucleus Pulposus Cells by Regulating the NF-KB and MAPK Signalling Pathway. Neurochem Res 2021;46:1390-9. [PMID: 33713325 DOI: 10.1007/s11064-021-03278-1] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
123 Deepak P, Loftus EV Jr. Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy. Drug Des Devel Ther 2016;10:3685-98. [PMID: 27956825 DOI: 10.2147/DDDT.S102141] [Cited by in Crossref: 29] [Cited by in F6Publishing: 8] [Article Influence: 5.8] [Reference Citation Analysis]
124 Salvador-Martín S, López-Cauce B, Nuñez O, Laserna-Mendieta EJ, García MI, Lobato E, Abarca-Zabalía J, Sanjurjo-Saez M, Lucendo AJ, Marín-Jiménez I, Menchén LA, López-Fernández LA. Genetic predictors of long-term response and trough levels of infliximab in crohn's disease. Pharmacol Res 2019;149:104478. [PMID: 31605784 DOI: 10.1016/j.phrs.2019.104478] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
125 Ilan Y. Immune rebalancing by oral immunotherapy: A novel method for getting the immune system back on track. J Leukoc Biol 2019;105:463-72. [PMID: 30476347 DOI: 10.1002/JLB.5RU0718-276RR] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
126 Reinglas J, Gonczi L, Verdon C, Bessissow T, Afif W, Wild G, Seidman E, Bitton A, Lakatos PL. Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center. Dig Dis Sci 2020;65:2046-53. [PMID: 31813132 DOI: 10.1007/s10620-019-05982-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
127 McKay KM, Apostolopoulos N, Chou B, Leveque TK, Van Gelder RN. Anti-adalimumab Antibodies in Patients with Non-infectious Ocular Inflammatory Disease: A Case Series. Ocul Immunol Inflamm 2021;:1-5. [PMID: 34270383 DOI: 10.1080/09273948.2021.1936565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Fiorino G, Manetti N, Armuzzi A, Orlando A, Variola A, Bonovas S, Bossa F, Maconi G, DʼIncà R, Lionetti P, Cantoro L, Fries W, Annunziata ML, Costa F, Terpin MM, Biancone L, Cortelezzi CC, Amato A, Ardizzone S, Danese S, Guidi L, Rizzuto G, Massella A, Andriulli A, Massari A, Lorenzon G, Ghione S, Kohn A, Ventra A, Annese V; PROSIT-BIO Cohort. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. Inflamm Bowel Dis 2017;23:233-43. [PMID: 28092307 DOI: 10.1097/MIB.0000000000000995] [Cited by in Crossref: 96] [Cited by in F6Publishing: 28] [Article Influence: 32.0] [Reference Citation Analysis]
129 Richter F, Seifert O, Herrmann A, Pfizenmaier K, Kontermann RE. Improved monovalent TNF receptor 1-selective inhibitor with novel heterodimerizing Fc. MAbs 2019;11:653-65. [PMID: 30929560 DOI: 10.1080/19420862.2019.1596512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
130 Chen P, Zhou G, Lin J, Li L, Zeng Z, Chen M, Zhang S. Serum Biomarkers for Inflammatory Bowel Disease. Front Med (Lausanne). 2020;7:123. [PMID: 32391365 DOI: 10.3389/fmed.2020.00123] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 19.0] [Reference Citation Analysis]
131 Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, Kroeker KI, Seow CH, Leung Y, Novak KL, Halloran BP, Huang VW, Wong K, Blustein PK, Ghosh S, Panaccione R. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017;45:1232-1243. [PMID: 28252210 DOI: 10.1111/apt.14016] [Cited by in Crossref: 85] [Cited by in F6Publishing: 80] [Article Influence: 21.3] [Reference Citation Analysis]
132 Oh EH, Ko DH, Seo H, Chang K, Kim GU, Song EM, Seo M, Lee HS, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Park SH. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease. World J Gastroenterol 2017; 23(8): 1489-1496 [PMID: 28293096 DOI: 10.3748/wjg.v23.i8.1489] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
133 Hirschmann S, Neurath MF. Top-down approach to biological therapy of Crohn's disease. Expert Opin Biol Ther 2017;17:285-93. [PMID: 28132526 DOI: 10.1080/14712598.2017.1287170] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
134 Hiraoka S, Takashima S, Kondo Y, Inokuchi T, Sugihara Y, Takahara M, Kawano S, Harada K, Kato J, Okada H. Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn's disease. Intest Res 2018;16:75-82. [PMID: 29422801 DOI: 10.5217/ir.2018.16.1.75] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
135 Gorelik Y, Freilich S, Gerassy-Vainberg S, Pressman S, Friss C, Blatt A, Focht G, Weisband YL, Greenfeld S, Kariv R, Lederman N, Dotan I, Geva-Zatorsky N, Shen-Orr SS, Kashi Y, Chowers Y; IIRN. Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN. Gut 2021:gutjnl-2021-325185. [PMID: 34344783 DOI: 10.1136/gutjnl-2021-325185] [Reference Citation Analysis]
136 Bar-yoseph H, Levhar N, Selinger L, Manor U, Yavzori M, Picard O, Fudim E, Kopylov U, Eliakim R, Ben-horin S, Chowers Y, Ungar B. Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy. Aliment Pharmacol Ther 2018;47:212-8. [DOI: 10.1111/apt.14410] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 8.8] [Reference Citation Analysis]